TrialThe oncologist2022

ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study.

Mark N Stein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.